Gene · 2642
GCGR: glucagon receptor
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. GCGR: glucagon receptor. Genes, record 2642. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/2642
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P47871 | Glucagon receptor | 477 | 27 | Ensembl, GeneID, HGNC |
Source UniProt
Patents113
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4777830 A1 | 2026-07-22 | 16 | P47871 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 47605 | P47871 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 11728 | P47871 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 5832 | P47871 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 1682 | P47871 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 6467 | P47871 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 1682 | P47871 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 6467 | P47871 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 11728 | P47871 | Espacenet |
| US 12269889 B2 | 2025-04-08 | 153 | P47871 | Espacenet |
1 to 10 of 113
See all 113 patentsDrugs15
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ADOMEGLIVANT | CHEMBL3707351 | Glucagon receptor antagonist | ANTAGONIST | ChEMBL |
| COTADUTIDE | CHEMBL4297630 | Glucagon receptor agonist | AGONIST | ChEMBL |
| CROTEDUMAB | CHEMBL3707278 | Glucagon receptor inhibitor | INHIBITOR | ChEMBL |
| DASIGLUCAGON | CHEMBL4297741 | Glucagon receptor agonist | AGONIST | ChEMBL |
| DASIGLUCAGON HYDROCHLORIDE | CHEMBL4650274 | Glucagon receptor agonist | AGONIST | ChEMBL |
| EFINOPEGDUTIDE | CHEMBL4297576 | Glucagon receptor agonist | AGONIST | ChEMBL |
| GLUCAGON | CHEMBL5314341 | Glucagon receptor agonist | AGONIST | ChEMBL |
| GLUCAGON HYDROCHLORIDE | CHEMBL5314342 | Glucagon receptor agonist | AGONIST | ChEMBL |
| MK-0893 | CHEMBL1933349 | Glucagon receptor antagonist | ANTAGONIST | ChEMBL |
| MK-3577 | CHEMBL1933350 | Glucagon receptor antagonist | ANTAGONIST | ChEMBL |
1 to 10 of 15
See all 15 drugsTrials173
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07467447 | RETATRUTIDE | PHASE2 | ClinicalTrials.gov | |
| NCT07357415 | RETATRUTIDE | PHASE3 | ClinicalTrials.gov | |
| NCT07232719 | RETATRUTIDE | PHASE3 | ClinicalTrials.gov | |
| NCT07212868 | VOLAGIDEMAB | PHASE1 | ClinicalTrials.gov | |
| NCT07206290 | SURVODUTIDE | PHASE2 | ClinicalTrials.gov | |
| NCT06982859 | RETATRUTIDE | PHASE1 | ClinicalTrials.gov | |
| NCT06982846 | RETATRUTIDE | PHASE1 | ClinicalTrials.gov | |
| NCT06859268 | RETATRUTIDE | PHASE3 | ClinicalTrials.gov | |
| NCT06854861 | GLUCAGON | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT06745284 | SURVODUTIDE | PHASE1 | ClinicalTrials.gov |
1 to 10 of 173
See all 173 trialsNIH grants907
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | GCGR papers | Newest fiscal year |
|---|---|---|---|
| P30DK020593 | Vanderbilt Diabetes Research Center | 18 | 2025 |
| P30DK058404 | Molecular and Cellular Basis for Digestive Diseases | 7 | 2025 |
| R35GM130307 | Development and Applications of Bioorthogonal Chemistry | 7 | 2025 |
| P30DK017047 | Diabetes Research Center | 6 | 2025 |
| I01BX000666 | Islet alterations in type 2 diabetes | 5 | 2025 |
| P30DK036836 | Diabetes Research Center | 5 | 2025 |
| P30DK056336 | UAB Nutrition Obesity Research Center (NORC) | 5 | 2025 |
| P30DK056341 | Washington University Nutrition Obesity Research Center | 5 | 2025 |
| T32DK007563 | Multidisciplinary Training in Molecular Endocrinology | 5 | 2025 |
| P30DK020572 | Michigan Diabetes Research Center (MDRC) | 4 | 2025 |
1 to 10 of 907Source NIH's project files
See all 907 nih grantsPapers2,157
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties. | Contemp Clin Trials | 2026 | 42822760 | PubTator, text mining | PubMed |
| Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes. | N Engl J Med | 2026 | 42820639 | PubTator, text mining | PubMed |
| Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis. | Diabetes Obes Metab | 2026 | 42811393 | PubTator, text mining | PubMed |
| Metabolic control by liver-kidney crosstalk and glucagon in health and disease. | Nat Rev Nephrol | 2026 | 42811087 | PubTator, text mining | PubMed |
| GLP-1 receptor agonists and podocyte senescence in diabetic kidney disease: structural pharmacology, mechanistic evidence, and multi-receptor agonism. | Biochem Pharmacol | 2026 | 42777788 | PubTator, text mining | PubMed |
| [New Therapeutic Approaches for MASH: Mechanisms and Clinical Promise]. | Z Gastroenterol | 2026 | 42777699 | PubTator, text mining | PubMed |
| Approach to the patient with primary hyperglucagonemia. | J Clin Endocrinol Metab | 2026 | 42766419 | PubTator, text mining | PubMed |
| Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis. | Rapid Commun Mass Spectrom | 2026 | 42745421 | PubTator, text mining | PubMed |
| Structural basis for small-molecule agonism at GCGR and GIPR via a conserved intracellular allosteric site. | Acta Pharmacol Sin | 2026 | 42736455 | PubTator, text mining | PubMed |
| Cardiovascular effects of incretin receptor agonists: beyond glycemic control. | Can J Physiol Pharmacol | 2026 | 42721492 | PubTator, text mining | PubMed |
1 to 10 of 2,157
See all 2,157 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/2642
GET https://conductscience.org/api/genes/v1/2642/patents?page=2